Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families - PubMed (original) (raw)
. 2007 Mar 16;282(11):7825-32.
doi: 10.1074/jbc.M609168200. Epub 2007 Jan 22.
Affiliations
- PMID: 17244626
- DOI: 10.1074/jbc.M609168200
Free article
Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families
Minji Kim et al. J Biol Chem. 2007.
Free article
Abstract
Insulin-degrading enzyme (IDE) is a zinc metalloprotease that degrades the amyloid beta-peptide, the key component of Alzheimer disease (AD)-associated senile plaques. We have previously reported evidence for genetic linkage and association of AD on chromosome 10q23-24 in the region harboring the IDE gene. Here we have presented the first functional assessment of IDE in AD families showing the strongest evidence of the genetic linkage. We have examined the catalytic activity and expression of IDE in lymphoblast samples from 12 affected and unaffected members of three chromosome 10-linked AD pedigrees in the National Institute of Mental Health AD Genetics Initiative family sample. We have shown that the catalytic activity of cytosolic IDE to degrade insulin is reduced in affected versus unaffected subjects of these families. Further, we have shown the decrease in activity is not due to reduced IDE expression, suggesting the possible defects in IDE function in these AD families. In attempts to find potential mutations in the IDE gene in these families, we have found no coding region substitutions or alterations in splicing of the canonical exons and exon 15b of IDE. We have also found that total IDE mRNA levels are not significantly different in sporadic AD versus age-matched control brains. Collectively, our data suggest that the genetic linkage of AD in this set of chromosome 10-linked AD families may be the result of systemic defects in IDE activity in the absence of altered IDE expression, further supporting a role for IDE in AD pathogenesis.
Similar articles
- Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.
Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ. Farris W, et al. Biochemistry. 2005 May 3;44(17):6513-25. doi: 10.1021/bi0476578. Biochemistry. 2005. PMID: 15850385 - Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain.
Blomqvist ME, Chalmers K, Andreasen N, Bogdanovic N, Wilcock GK, Cairns NJ, Feuk L, Brookes AJ, Love S, Blennow K, Kehoe PG, Prince JA. Blomqvist ME, et al. Neurobiol Aging. 2005 Jun;26(6):795-802. doi: 10.1016/j.neurobiolaging.2004.07.011. Neurobiol Aging. 2005. PMID: 15718037 Clinical Trial. - Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein.
Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ. Farris W, et al. Am J Pathol. 2004 Apr;164(4):1425-34. doi: 10.1016/s0002-9440(10)63229-4. Am J Pathol. 2004. PMID: 15039230 Free PMC article. - Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
Qiu WQ, Folstein MF. Qiu WQ, et al. Neurobiol Aging. 2006 Feb;27(2):190-8. doi: 10.1016/j.neurobiolaging.2005.01.004. Epub 2005 Feb 17. Neurobiol Aging. 2006. PMID: 16399206 Review. - [Cerebral proteolysis of amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease].
Leal MC, Fernandez Gamba A, Morelli L, Castaño EM. Leal MC, et al. Medicina (B Aires). 2009;69(4):466-72. Medicina (B Aires). 2009. PMID: 19770104 Review. Spanish.
Cited by
- Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis.
Dong S, Duan Y, Hu Y, Zhao Z. Dong S, et al. Transl Neurodegener. 2012 Sep 21;1(1):18. doi: 10.1186/2047-9158-1-18. Transl Neurodegener. 2012. PMID: 23210692 Free PMC article. - Comparative protein interactomics of neuroglobin and myoglobin.
Haines BA, Davis DA, Zykovich A, Peng B, Rao R, Mooney SD, Jin K, Greenberg DA. Haines BA, et al. J Neurochem. 2012 Oct;123(1):192-8. doi: 10.1111/j.1471-4159.2012.07881.x. Epub 2012 Aug 14. J Neurochem. 2012. PMID: 22816983 Free PMC article. - Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.
Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS. Wang S, et al. J Neurochem. 2010 Oct;115(1):47-57. doi: 10.1111/j.1471-4159.2010.06899.x. Epub 2010 Jul 30. J Neurochem. 2010. PMID: 20663017 Free PMC article. - Impaired amyloid β-degrading enzymes in brain of streptozotocin-induced diabetic rats.
Liu Y, Liu L, Lu S, Wang D, Liu X, Xie L, Wang G. Liu Y, et al. J Endocrinol Invest. 2011 Jan;34(1):26-31. doi: 10.1007/BF03346691. Epub 2010 Apr 22. J Endocrinol Invest. 2011. PMID: 20414044 - Alzheimer's Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms between Alzheimer's Disease and Type 2 Diabetes.
Michailidis M, Moraitou D, Tata DA, Kalinderi K, Papamitsou T, Papaliagkas V. Michailidis M, et al. Int J Mol Sci. 2022 Feb 28;23(5):2687. doi: 10.3390/ijms23052687. Int J Mol Sci. 2022. PMID: 35269827 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous